Schöler David, Loosen Sven H, Wirtz Theresa H, Brozat Jonathan F, Dos Santos Ferreira Grani Lauredana A, Luedde Tom, Heinrichs Lisa, Frank Derk, Koch Alexander, Roderburg Christoph, Spehlmann Martina E
Clinic for Gastroenterology, Hepatology and Infectious Diseases, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
Department of Gastroenterology, Digestive Diseases and Intensive Care Medicine, RWTH Aachen University Hospital, Aachen, Germany.
Front Cardiovasc Med. 2023 May 24;10:1163525. doi: 10.3389/fcvm.2023.1163525. eCollection 2023.
Heart disease is of worldwide importance due to high morbidity and mortality. Extracellular vesicle (EV) concentration and size represent novel diagnostic and prognostic biomarkers, e.g. in patients with liver cancer, but data on their prognostic relevance in heart disease are lacking. Here, we investigated the role of EV concentration, size and zeta potential in patients with heart disease.
Vesicle size distribution, concentration and zeta potential were measured by nanoparticle tracking analysis (NTA) in 28 intensive care unit (ICU) and 20 standard care (SC) patients and 20 healthy controls.
Patients with any disease had a lower zeta potential compared to the healthy controls. Vesicle size (X50) was significantly higher in ICU patients (245 nm) with heart disease as compared to those patients with heart disease receiving standard care (195 nm), or healthy controls (215 nm) ( = 0.001). Notably, EV concentration was lower in ICU patients with heart disease (4.68 × 10 particles/ml) compared to SC patients with heart disease (7,62 × 10 particles/ml) and healthy controls (1.50 × 10 particles/ml) ( = 0.002). Extracellular vesicle concentration is prognostic for overall survival in patients with heart disease. Overall survival is significantly reduced when the vesicle concentration is below 5.55 × 10 particles/ml. Median overall survival was only 140 days in patients with vesicle concentrations below 5.55 × 10 particles/ml compared to 211 days in patients with vesicle concentrations above 5.55 × 10 particles/ml ( = 0.032).
Concentration of EVs is a novel prognostic marker in ICU and SC patients with heart disease.
由于高发病率和死亡率，心脏病在全球范围内具有重要意义。细胞外囊泡（EV）的浓度和大小代表了新的诊断和预后生物标志物，例如在肝癌患者中，但关于它们在心脏病中的预后相关性的数据尚缺乏。在此，我们研究了EV浓度、大小和zeta电位在心脏病患者中的作用。
通过纳米颗粒跟踪分析（NTA）测量了28名重症监护病房（ICU）患者、20名标准护理（SC）患者和20名健康对照者的囊泡大小分布、浓度和zeta电位。
与健康对照相比，任何疾病患者的zeta电位均较低。患有心脏病的ICU患者（245nm）的囊泡大小（X50）显著高于接受标准护理的心脏病患者（195nm）或健康对照者（215nm）（P = 0.001）。值得注意的是，患有心脏病的ICU患者的EV浓度（4.68×10颗粒/毫升）低于患有心脏病的SC患者（7.62×10颗粒/毫升）和健康对照者（1.50×10颗粒/毫升）（P = 0.002）。细胞外囊泡浓度可预测心脏病患者的总体生存率。当囊泡浓度低于5.55×10颗粒/毫升时，总体生存率显著降低。囊泡浓度低于5.55×10颗粒/毫升的患者的中位总体生存期仅为140天，而囊泡浓度高于5.55×10颗粒/毫升的患者为211天（P = 0.032）。
EV的浓度是ICU和SC心脏病患者的一种新的预后标志物。
